Spots Global Cancer Trial Database for poly iclc
Every month we try and update this database with for poly iclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | NCT01188096 | Brain Tumors | Poly ICLC | - 21 Years | Wake Forest University Health Sciences | |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | NCT04201873 | Recurrent Gliob... | Dendritic Cell ... Pembrolizumab Placebo Adminis... Poly ICLC | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | NCT02427581 | Triple Negative... Triple Negative... Triple-Negative... | Personalized sy... Poly ICLC | 18 Years - | Washington University School of Medicine | |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | NCT02126579 | Melanoma Metastatic Mela... Mucosal Melanom... | Peptide Vaccine... PolyICLC Resiquimod IFA | 18 Years - | University of Virginia | |
| Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | NCT02061449 | Cutaneous T-cel... | Romidepsin Poly ICLC Focal lesional ... | 18 Years - | NYU Langone Health | |
| Vaccination With Flt3L, Radiation, and Poly-ICLC | NCT03789097 | Non-Hodgkin's L... Metastatic Brea... Head and Neck S... | Pembrolizumab Flt3L Radiation Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients | NCT05281926 | Hepatocellular ... | Poly ICLC | 20 Years - | National Taiwan University Hospital | |
| Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | NCT03606967 | Anatomic Stage ... Invasive Breast... Metastatic Trip... | Biopsy Biospecimen Col... Carboplatin Computed Tomogr... Durvalumab Gemcitabine Hyd... Magnetic Resona... Nab-paclitaxel Personalized Sy... Poly ICLC Tremelimumab | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | NCT01842139 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... | basiliximab WT1 126-134 pep... Montanide ISA 5... poly ICLC laboratory biom... | 18 Years - 85 Years | University of Chicago | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | NCT03956056 | Pancreas Cancer Pancreatic Canc... Cancer of the P... | Neoantigen Pept... Poly ICLC Blood for immun... | 18 Years - | Washington University School of Medicine | |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | NCT01842139 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... | basiliximab WT1 126-134 pep... Montanide ISA 5... poly ICLC laboratory biom... | 18 Years - 85 Years | University of Chicago | |
| Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma | NCT00058123 | Brain and Centr... | poly ICLC | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase II Trial of Poly-ICLC for Low-Grade Gliomas | NCT04544007 | NF1 Low-grade Gliom... | Poly ICLC | - 22 Years | University of Alabama at Birmingham | |
| Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | NCT03606967 | Anatomic Stage ... Invasive Breast... Metastatic Trip... | Biopsy Biospecimen Col... Carboplatin Computed Tomogr... Durvalumab Gemcitabine Hyd... Magnetic Resona... Nab-paclitaxel Personalized Sy... Poly ICLC Tremelimumab | 18 Years - | National Cancer Institute (NCI) | |
| Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer | NCT03166254 | Non Small Cell ... NSCLC Non-small Cell ... Small Cell Lung... | Pembrolizumab NEO-PV-01 vacci... Biopsy Poly ICLC Leukapheresis Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | NCT01188096 | Brain Tumors | Poly ICLC | - 21 Years | Wake Forest University Health Sciences | |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | NCT01842139 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... | basiliximab WT1 126-134 pep... Montanide ISA 5... poly ICLC laboratory biom... | 18 Years - 85 Years | University of Chicago | |
| Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | NCT02061449 | Cutaneous T-cel... | Romidepsin Poly ICLC Focal lesional ... | 18 Years - | NYU Langone Health | |
| Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells | NCT01783431 | Melanoma | Poly ICLC leukapheresis | 18 Years - | Medical University of South Carolina | |
| Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00052715 | Brain and Centr... | poly ICLC | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors | NCT03068832 | Pediatric Brain... | Personalized pe... Poly ICLC Peripheral bloo... | - 21 Years | Washington University School of Medicine | |
| Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | NCT03121677 | Follicular Lymp... | Personalized tu... Poly ICLC Nivolumab Peripheral bloo... Leukapheresis Rituximab Biopsy | 18 Years - | Washington University School of Medicine | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | NCT04616248 | Anatomic Stage ... Metastatic Brea... Prognostic Stag... Unresectable Br... Metastatic Mela... Unresectable Me... Cutaneous Squam... Merkel Cell Car... Soft Tissue Sar... Bone Sarcoma Sarcoma,Soft Ti... Sarcoma of Bone | Anti-CD40 Agoni... Poly ICLC Radiation Thera... Recombinant Flt... | 18 Years - | University of Southern California | |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | NCT05457959 | Diffuse Hemisph... | Dendritic Cell ... Ipilimumab Leukapheresis Nivolumab Placebo Adminis... Placebo Adminis... Poly ICLC Resection | 13 Years - 60 Years | Jonsson Comprehensive Cancer Center | |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | NCT04201873 | Recurrent Gliob... | Dendritic Cell ... Pembrolizumab Placebo Adminis... Poly ICLC | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM | NCT00262730 | Glioblastoma Mu... | poly ICLC temozolomide radiation thera... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | NCT00553683 | Breast Cancer Colorectal Canc... Gastric Cancer Liver Cancer Melanoma (Skin) Metastatic Canc... Ovarian Cancer Pancreatic Canc... | cyclophosphamid... poly ICLC hepatic artery ... 3-dimensional c... | 18 Years - 75 Years | Rutgers, The State University of New Jersey | |
| A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma | NCT01677962 | Pancreatic Aden... | Poly-ICLC dendritic cell | 18 Years - | Medical University of South Carolina | |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | NCT06342908 | Diffuse Hemisph... | Biospecimen Col... Dendritic Cell ... Leukapheresis Magnetic Resona... Poly ICLC | 18 Years - 50 Years | Jonsson Comprehensive Cancer Center | |
| MUC1 Vaccine for Triple-negative Breast Cancer | NCT00986609 | Breast Cancer Inflammatory Br... Stage I Breast ... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | MUC-1 peptide v... poly ICLC MUC1 peptide-po... laboratory biom... enzyme-linked i... flow cytometry | 18 Years - | Case Comprehensive Cancer Center | |
| Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma | NCT01920191 | CNS Tumor, Adul... | IMA 950 Poly ICLC Immunomonitorin... | 18 Years - | University Hospital, Geneva | |
| A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma | NCT01677962 | Pancreatic Aden... | Poly-ICLC dendritic cell | 18 Years - | Medical University of South Carolina | |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | NCT04116320 | Melanoma Breast Cancer Merkel Cell Car... Squamous Cell C... Non Small Cell ... Cervical Cancer Urothelial Carc... Ovarian Cancer Hepatocellular ... Small-cell Lung... Microsatellite ... Gastric Cancer Esophageal Canc... | Echopulse Poly ICLC Standard of Car... | 18 Years - | University of Virginia | |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | NCT05025488 | Myelofibrosis Essential Throm... MPN | Peptide-based v... Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
